Basel, August 8, 2024 – Novartis today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Fabhalta (iptacopan), a first-in-class complement inhibitor for the reduction of proteinuria in adults with…Original Article
Novartis Receives FDA Accelerated Approval for Fabhalta (iptacopan) for the Reduction of Proteinuria in Primary IgA Nephropathy (IgAN)
